Artrya Limited (AU:AYA)
ASX:AYA
Top Page
Artrya Limited
(Sydney:AYA)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$2.50
▼(-20.13% Downside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by weak financial performance (large ongoing losses and cash burn), partially offset by a relatively conservative balance sheet. Technical indicators add pressure with bearish momentum despite oversold readings, while valuation offers little support due to negative earnings and no dividend.
Positive Factors
Balance sheet strength
Low leverage and a modest debt profile give Artrya structural financial flexibility despite operating losses. Over the next 2–6 months this reduces insolvency risk, supports continued R&D and regulatory work, and makes external financing or partnerships easier to pursue without immediate distress.
Negative Factors
High cash burn
Consistently negative operating and free cash flow at material levels implies ongoing funding needs. Over a multi-month horizon this creates execution risk: management must secure financing or partnerships to continue operations, which can dilute shareholders or divert focus from commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Low leverage and a modest debt profile give Artrya structural financial flexibility despite operating losses. Over the next 2–6 months this reduces insolvency risk, supports continued R&D and regulatory work, and makes external financing or partnerships easier to pursue without immediate distress.
Read all positive factors
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$494.80M
Dividend YieldN/A
Average Volume (3M)878.02K
Price to Earnings (P/E)―
Beta (1Y)1.95
Revenue GrowthN/A
EPS Growth0.17%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.09
Shares Outstanding158,084,010
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.27Price Target Upside100.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$10.00M
Artrya Limited Business Overview & Revenue Model
Company Description
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary ...
How the Company Makes Money
null...
Artrya Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
15
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.00K | 28.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.60M | -15.99M | -13.25M | -552.00K | -202.00K | -38.51K |
| EBITDA | -21.92M | -16.21M | -13.96M | -10.51M | -16.40M | -4.01M |
| Net Income | -19.71M | -16.41M | -14.00M | -11.14M | -17.16M | -4.08M |
Balance Sheet | ||||||
| Total Assets | 92.19M | 23.68M | 19.01M | 33.09M | 43.87M | 52.22M |
| Cash, Cash Equivalents and Short-Term Investments | 76.67M | 11.33M | 7.28M | 20.41M | 35.56M | 50.13M |
| Total Debt | 546.00K | 624.00K | 949.00K | 1.21M | 1.37M | 84.42K |
| Total Liabilities | 2.84M | 2.39M | 2.21M | 2.53M | 3.23M | 1.17M |
| Stockholders Equity | 89.35M | 21.29M | 16.80M | 30.56M | 40.64M | 51.05M |
Cash Flow | ||||||
| Free Cash Flow | -21.38M | -14.53M | -15.41M | -16.69M | -15.99M | -3.55M |
| Operating Cash Flow | -21.08M | -14.27M | -15.41M | -10.74M | -9.61M | -1.49M |
| Investing Cash Flow | -30.30M | 7.00K | 2.71M | 16.27M | -26.59M | -1.86M |
| Financing Cash Flow | 90.07M | 18.46M | -299.00K | -245.00K | 38.53M | 14.10M |
Artrya Limited Technical Analysis
Negative
3.13
Price Trends
3.29
Negative
3.57
Negative
2.74
Positive
Market Momentum
-0.03
Negative
49.06
Neutral
70.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AYA, the sentiment is Negative. The current price of 3.13 is above the 20-day moving average (MA) of 3.12, below the 50-day MA of 3.29, and above the 200-day MA of 2.74, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 49.06 is Neutral, neither overbought nor oversold. The STOCH value of 70.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AYA.
Artrya Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$20.04M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
46 Neutral | AU$494.80M | -13.78 | -35.63% | ― | ― | 0.17% | |
44 Neutral | AU$42.87M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$71.03M | -6.64 | -59.96% | ― | ― | ― | |
41 Neutral | AU$8.23M | -0.96 | 152.58% | ― | -40.05% | -49.57% |
* Healthcare Sector Average
AU:AYA
Artrya Limited
3.13
2.52
413.11%
AU:RHT
Resonance Health Ltd
0.04
<0.01
20.00%
AU:BMT
Beamtree Holdings Ltd
0.15
-0.05
-26.50%
AU:SHG
Singular Health Group Ltd
0.23
0.02
12.50%
AU:HIQ
HitIQ Limited
0.01
-0.01
-51.85%
Artrya Limited Corporate Events
Artrya Strengthens Governance With Appointment of New Company Secretary
Mar 17, 2026
Artrya Limited has announced a change in its corporate leadership, appointing experienced governance specialist Mark Pitts as company secretary following the retirement of Kevin Hart. Pitts, a principal at Automic Group with more than three decade...
Artrya reports lapse of 10,000 performance rights
Mar 9, 2026
Artrya Limited has reported the lapse of 10,000 performance rights, designated under the ASX code AYAAAF, after the conditions attached to those rights were not met or became incapable of being satisfied. The cessation, effective 9 March 2026, rep...
Artrya launches non-deal roadshow ahead of Bell Potter healthcare showcase
Mar 8, 2026
Artrya Limited has begun an Australian non-deal roadshow, with co-founder and CEO John Konstantopoulos and executive chair Bernie Ridgeway meeting existing and prospective investors and research analysts in Sydney and Melbourne. The company has re...
S&P Dow Jones Indices Unveils March 2026 S&P/ASX Index Rebalance
Mar 6, 2026
SP Dow Jones Indices has announced a broad reshuffle across the SP/ASX indices effective before trading on March 23, 2026, adjusting constituents in the SP/ASX 20, 50, 100, 200, and 300 to reflect market movements and updated eligibility. The chan...
Artrya’s Half-Year Loss Widens Despite Strong Rise in Net Tangible Assets
Feb 25, 2026
Artrya Limited reported a significant increase in its half-year loss for the six months to 31 December 2025, with the loss after tax attributable to owners widening 44.4% to $10.743 million from $7.441 million a year earlier. The company did not d...
Artrya Reports Lapse of 613,334 Performance Rights in Capital Update
Feb 20, 2026
Artrya Limited has notified the market of changes to its issued capital via an Appendix 3H filing, confirming the lapse of a tranche of performance rights. The update reflects routine capital management activity, with no additional context provide...
Artrya Enlists Dignity Health Arizona and Launches Female-Focused Cohort in SAPPHIRE Heart Study
Feb 1, 2026
Artrya Limited has secured in-principle participation from Dignity Health Arizona, part of CommonSpirit Health and one of the largest nonprofit healthcare systems in the United States, in its retrospective multi-centre SAPPHIRE Study, subject to f...
Artrya adds HCA Midwest Health to U.S. SAPPHIRE heart disease study
Jan 29, 2026
Artrya Limited has secured in-principle participation from HCA Midwest Health in its upcoming retrospective, multi-centre SAPPHIRE Study in the United States, pending protocol and ethics approval. The inclusion of HCA Midwest Health, a high-volume...
Artrya Names Interim CFO as It Bolsters Leadership for Next Growth Phase
Jan 27, 2026
Artrya Limited has appointed Richard Jarvis of The CFO Bridge as interim Chief Financial Officer, effective immediately, while it undertakes an executive search with Stanton Chase for a permanent CFO to lead the finance function through its next g...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.